Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
April 15, 1999
Which chemotherapy given concurrent with RT improves survival in women with locally advanced cervical cancer?
EBRT + brachyhydroxyurea 3g/m2 twice weekly
(1 ) EBRT + brachycisplatin 40mg/m2 weekly(2) EBRT + brachycisplatin 50mg/m2 day 1 and 295FU 4g/m2 day 1 and 20hydroxyurea 2mg/m2 twice weekly
PFS
squamous, adenosquamous, adenostage IIB - IVA
disease outside of pelvispara-aortic LN metastasesintra-abdominal metastases
hydroxyurea (n=177) vs cis (n=176) vs cis/5FU/hydroxyurea (n=173):grade 3/4 leukopenia: 21% vs 23% vs 46% (SS)median f/u: 35 mosRR progression: 0.57 (SS) for cis and 0.55 (SS) for cis/5FU/hydroxyurea24mos PFS: 47% vs 67% vs 64%RR death: 0.61 (SS) for cis and 0.58 (SS) for cis/5FU/hydroxyurea
RT with concurrent platinum-based chemotherapy improves survival in women with locally advanced cervical cancer